We focused on TP53-mutant AML/MDS because current therapeutic approaches, i.e., intensive induction chemotherapy or HMAs+/− Ven have failed to improve patient outcomes (Pollyea et al, 2022), and thus, immunotherapeutic strategies are currently being tested in this clinically challenging patient cohort (Sallman et al, 2022). The gene discussed is TP53; the disease is myelodysplastic syndrome.